New Genentech Data at 2021 AAN Highlight Impact and Breadth of Expanding Neuroscience Portfolio

Published Apr 08 2021 at 5:00 AM GMT
  • " Evrysdi (risdiplam) 2-year FIREFISH Part 2 data show improvement in motor function in infants with Type 1 spinal muscular atrophy (SMA) " ' Ocrevus (ocrelizumab) data show its consistent benefit on slowing disease progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS) ' ' Data for Enspryng (satralizumab-mwge) in neuromyelitis optica spectrum disorder (NMOSD) reinforce safety and efficacy, including in patients with concomitant autoimmune diseases (CAIDs) ' ' Data for investigational MS medicine fenebrutinib support its safety profile and high potency ' ' Additional presentations on investigational programs, including Alzheimer's disease and Huntington's disease, help advance scientific understanding of neurological disorders ' Genentech, a member of the Roche Group ((SIX: RO, ROG, OTCQX:RHHBY), today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually April 17-22, 2021.
  • These new data include 23 abstracts highlighting the expanding Genentech neuroscience portfolio across six therapeutic areas, including Evrysdi™ (risdiplam) for spinal muscular atrophy (SMA), Ocrevus® (ocrelizumab) in relapsing and primary progressive multiple sclerosis (RMS and PPMS), investigational Bruton's tyrosine kinase inhibitor (BTKi) fenebrutinib in Phase III trials for RMS and PPMS, Enspryng™ (satralizumab-mwge) in neuromyelitis optica spectrum disorder (NMOSD), and data from investigational programs in Alzheimer's disease (AD) and Huntington's disease (HD).
  • "Following US FDA and global approvals for our groundbreaking therapies in SMA and NMOSD, Roche and Genentech's data at AAN reflect our continued commitment to meaningful therapeutic progress for people living with neurological disorders," said Levi Garraway, M D, Ph.
  • D, chief medical officer and head of Global Product Development.
  • "We are proud to collaborate with patient advocates, academi.


  • Published Apr 8, 2021 5:00 AM GMT